mardi 3 mars 2020

Onco Actu du 3 mars 2020


1. BIOLOGIE



Science Surgery: ‘Are benign tumours different from cancerous tumours?’ [Cancer Research UK]











2.13 ETIOLOGIE - NDMA



Testing lab challenges FDA findings that carcinogens in metformin do not exceed acceptable levels [Fierce Pharma]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Is vaping safe? What the latest research says about the cigarette substitute [The Telegraph]











4.1 DÉP., DIAG. & PRONO. - PROSTATE



Before Prostate Surgery, Consider ‘Active Surveillance’ [NY Times]










4.2 DÉP., DIAG. & PRONO. - GÉNOME



Mayo researchers recommend all women with breast cancer diagnosis under age 66 be offered genetic testing [Mayo Clinic]










4.9 DÉP., DIAG. & PRONO. - SEIN



Study: AI improves radiologists’ readings of mammograms [UW Medicine]











5.12.10 IMMUNOTHÉRAPIES - FUSIONS ET ACQUISITIONS



Gilead strikes $4.9B Forty Seven acquisition, paying a hefty premium for cancer drug [Fierce Biotech]











Gilead Boosts Cancer Drug Pipeline With $4.9B Deal for Forty Seven [Xconomy]










Gilead breaks M&A lull with $5B immuno-oncology deal [Biopharma Dive]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Vitamin C and Immuno-oncology [In The Pipeline]










5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



FDA Accepts MorphoSys' Biologics License Application (BLA) and Grants Priority Review for Tafasitamab and Lenalidomide for the Treatment of Relapsed/Refractory DLBCL (news with additional features) [MorphoSys]











MorphoSys’ off-the-shelf rival to CAR-T approaches finish line with a speedy review [EndPoints]










5.12.5 IMMUNOTHÉRAPIES - PHARMA



Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) [Merck]











Merck clears PFS endpoint in confirmatory trial for Keytruda in classical Hodgkin lymphoma [EndPoints]











5.12.5.1.1 IMMUNOTHÉRAPIES - BIOTECH - IMMUNOCORE



Immunocore raises $130M to fund pivotal cancer program [Fierce Biotech]











Woodford who? TCR-focused Immunocore soldiers on with $130M+ B round [EndPoints]











5.12.5.1.2 IMMUNOTHÉRAPIES - BIOTECH - XILIO



Akrevia no more, Xilio Therapeutics bags $101M for I-O programs [Fierce Biotech]











Xilio Unveils New Name, $100M to Bring Targeted Cancer Drugs to Clinic [Xconomy]











Ex nihilo: Takeda leads $100M+ round to fund biotech's sneak attack on tumors, propelling new IL-2, CTLA-4 drugs to clinic [EndPoints]











5.2 PHARMA



AbbVie, Roche's Venclexta endangers AML approval with flopped confirmatory trial [Fierce Pharma]











Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer [Takeda]











5.2.6 PHARMA - BIOTECH



ORIC Pharma Plans IPO to Test Therapies for Drug-Resistant Cancers [Xconomy]











5.2.6.1 PHARMA - BIOTECH - KARYOPHARM



Karyopharm shares jump on positive study data for multiple myeloma drug [Biopharma Dive]











Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy [Karyopharm]











Karyopharm spotlights PhIII results after controversial FDA approval [EndPoints]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Sanofi wins US approval for myeloma drug key to its cancer ambitions [Biopharma Dive]











Ending a grueling 10-year drought, Sanofi finally wins an OK for an in-house cancer drug [EndPoints]











FDA approves isatuximab-irfc for multiple myeloma [FDA]










6. LUTTE CONTRE LES CANCERS



Squaring up to silent tumours: the research burden of pancreatic cancer [Institute of Cancer Research]